1982
DOI: 10.1016/0091-3057(82)90062-4
|View full text |Cite
|
Sign up to set email alerts
|

Phencyclidine raises kindled seizure thresholds

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
12
0

Year Published

1985
1985
2016
2016

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 32 publications
(12 citation statements)
references
References 5 publications
0
12
0
Order By: Relevance
“… 5 7 Ketamine is a noncompetitive N -methyl- d -aspartate receptor antagonist 23 that might play a role in treating seizure in status epilepticus by blocking N -methyl- d -aspartate receptor-mediated glutamatergic neurotransmission. 24 , 25 Besides, Kolesnikov et al 9 reported that ketamine could prevent morphine-induced myoclonus in mice, which is consistent with a clinical report introduced by Forero et al 10 that low-dose ketamine effectively relieved the painful myoclonus in a patient receiving long-term opioids treatment. In this study, we chose the low-dose ketamine because: low-dose ketamine has shown its capacity to prevent the painful myoclonus 10 ; low-dose ketamine administration over 30 seconds could get rid of the psychiatric symptoms induced by large doses (>2 mg/kg, IV) and rapid injection of ketamine (>40 mg/min) 26 ; low-dose ketamine premedication has been suggested to be beneficial in improving intubating condition and managing postoperative analgesia.…”
Section: Discussionmentioning
confidence: 55%
“… 5 7 Ketamine is a noncompetitive N -methyl- d -aspartate receptor antagonist 23 that might play a role in treating seizure in status epilepticus by blocking N -methyl- d -aspartate receptor-mediated glutamatergic neurotransmission. 24 , 25 Besides, Kolesnikov et al 9 reported that ketamine could prevent morphine-induced myoclonus in mice, which is consistent with a clinical report introduced by Forero et al 10 that low-dose ketamine effectively relieved the painful myoclonus in a patient receiving long-term opioids treatment. In this study, we chose the low-dose ketamine because: low-dose ketamine has shown its capacity to prevent the painful myoclonus 10 ; low-dose ketamine administration over 30 seconds could get rid of the psychiatric symptoms induced by large doses (>2 mg/kg, IV) and rapid injection of ketamine (>40 mg/min) 26 ; low-dose ketamine premedication has been suggested to be beneficial in improving intubating condition and managing postoperative analgesia.…”
Section: Discussionmentioning
confidence: 55%
“…Excessive excitatory transmission may also char- acterize other models of seizure proclivity with similarities to metaphit. A role for the NMDAIPCP complex has been documented in brainstem seizures of genetic models of the epilepsies (Chapman and Meldrum, 1989;Faingold et al, 1992) and in kindling (Freeman et al, 1982;Glibert, 1988;Leander et al, 1988;McNamara et al, 1988;Morimoto and Sato, 1992). This proposed commonality in excessive excitatory transmission by the NMDA/PCP receptor complex may be responsible for the similar pharmacologic profiles that characterize some of the effects of metaphit and NMDA.…”
Section: Epilepsiamentioning
confidence: 99%
“…Subsequently, this process induced continuously amplified neuronal hyperexcitability, leading to the development of RSE. Ketamine is a noncompetitive NMDA receptor antagonist [16] that might play a role in treating SE by blocking NMDA receptor-mediated glutamatergic neurotransmission [17,18]. Moreover, by blocking glutamatemediated NMDA receptor-induced neurotoxicity, ketamine also exerts neuroprotection [19][20][21].…”
Section: Introductionmentioning
confidence: 99%